Since 2015, RejuvaTech has operated as a research-driven development platform focused on longevity chemistry, regenerative compound systems, and advanced delivery architecture.

Our work integrates contemporary peer-reviewed research with applied formulation science, emphasizing plant-derived bioactives, NAD⁺ precursor evolution, and telomere-supportive compound classes. Rather than relying on isolated ingredients, we focus on structural improvement — enhancing stability, systemic exposure, and delivery precision through engineered architectures.

Our triterpenoid composition platform reflects this approach, combining optimized synthesis with nanocarrier and SNEDDS delivery systems to support dermal and systemic regenerative applications. Parallel to this work, our NAD⁺-related research has progressed from first-generation nicotinamide riboside formulations to stabilized next-generation precursor systems engineered for improved intracellular conversion efficiency.

Throughout this evolution, our objective has remained consistent: to develop protected, scalable, and commercially viable chemistry platforms capable of supporting premium wellness portfolios with measurable performance differentiation.

Bret M. Lee is a biochemist and longevity researcher with more than four decades of experience in chemistry, cellular biology, and applied health science.

As Chief Scientist of RejuvaTech, he leads research focused on protected longevity precursor systems, regenerative triterpenoid platforms, and advanced bioavailability architectures. His work centers on stabilizing and enhancing bioactive compound classes to improve intracellular performance, systemic exposure, and commercial scalability.

Mr. Lee’s expertise in natural product chemistry and structural optimization has guided the development of multiple patent-pending platforms, including next-generation NAD⁺ precursor compositions and integrated nanocarrier delivery systems. His research approach combines mechanistic cellular understanding with practical formulation science, bridging laboratory innovation with structured commercialization pathways.

Dr. Santiago T. Peña, Jr. is an academic leader and biotechnology researcher with extensive experience in clinical study design, translational research, and institutional research governance.

As Vice President for Research, Extension, and Innovation at Visayas State University, Dr. Peña oversees multidisciplinary research initiatives, including biotechnology and health-focused programs. His leadership role provides structured oversight for clinical research development, protocol design, data management, and institutional compliance frameworks.

Within RejuvaTech’s research program, Dr. Peña will play a critical role in supervising clinical trial planning and execution across multiple intellectual property platforms, ensuring scientific rigor, ethical compliance, and data integrity. His involvement supports the transition of protected chemistry platforms from preclinical modeling to formal clinical validation.

Alice Sun serves as Director of Technology Transfer and oversees synthesis coordination, precursor sourcing, and manufacturing integration across RejuvaTech’s compound platforms.

With advanced training in chemistry and management, she manages the structured transfer of protected compositions — including stabilized NRH architectures and triterpenoid systems — from laboratory development to scaled manufacturing environments. Her role includes procurement oversight of critical analogs and precursors, vendor qualification, and alignment of synthesis protocols with GMP production partners.

Ms. Sun’s interdisciplinary background in chemistry, business, and economic systems supports disciplined cost management, supply chain resilience, and scalable production architecture — ensuring that RejuvaTech’s protected platforms can transition efficiently from innovation to commercial deployment.